Cambridge’s reputation as a hotspot for medical device innovation has been ramped up a few extra notches by the progress of young and increasingly powerful consultancy Springboard.
Aseptika in Cambridge UK has accelerated development of its medical wearable Smartwatch, the BuddyWOTCH, which is aimed at a market worth an estimated $2 billion.
Crescendo Biologics in Cambridge UK has secured a further equity investment from Astellas Venture Management (AVM) to support the discovery and development of new Humabody antibody fragment therapeutics in oncology.
A new genomics powerhouse, spun out of the world famous Wellcome Trust Sanger Institute, has been launched in the Cambridge UK technology cluster with a £12.5 million financing.
Life science company Abzena is already reaping the benefits of moving its corporate HQ to the Cambridge UK medical technology cluster.
Global consumer products giant Procter & Gamble (P&G) has turned to Cambridge bioinformatics technology to accelerate certain areas of research.
Horizon Discovery, the Cambridge UK medical technology trailblazer, has lined up a new multi-billion pound market with a significant first deal in the segment.
A technology collaboration between Cambridge UK text analytics specialist Linguamatics and the IP and science business of Thomson Reuters in Philadelphia will lead to more effective clinical trials and drug discovery, the partners believe.
Congenica, a Cambridge UK genomics company whose technology will allow definitive diagnosis of children with rare genetic diseases in minutes rather than years, has secured up to £1 million funding from Cambridge Innovation Capital.
The China Patent & Trademark Office has granted Cambridge-based Sareum a patent for one the medical technology company's key drug discovery inventions.
Consort Medical, the Cambridge-based medical technology group, gained a healthy injection to its UK share price on the back of interim revenue growth.
Horizon Discovery CEO Darrin Disley has scooped one of the top honours in the life science industry after being named Executive of the Year at last night’s SCRIP Awards in London.
Sagentia, the Cambridge UK technology innovator, is working on what is said to be the world’s first programmable and wearable nicotine delivery device to help people quit smoking.
A trio of medical initiatives from Cambridge University have been chosen out of hundreds of applications from around the world to be fast-tracked to commercialisation by drugs giant GSK.
The bottom line clearly means more to biotech investors than potential in the portfolio as widening losses sent the shares of Cambridge medical technology business GW Pharmaceuticals sharply south in the UK.
Cambridge is to host an historic alliance between scientists at AstraZeneca and investigators at Cancer Research UK designed to push the boundaries of cancer discovery and generate new drugs.
- Pfizer invests in $32 million MISSION funding round
- Personalised medicines boost from UK-US alliance
- Cambridge stem cell pioneer targets China partners
- Endomagnetics raises £2m for US trial and cancer marker launch
- Horizon clinches $750k deal with Top 10 pharma giant
- Shanghai plans healthcare future with help from Cambridge medics
- Owlstone unveils new manufacturing facility
- Scientists seek funds to grow lung tissue in the lab
- Sareum secures European patent for auto immune disease technology
- Cambridge startup hopes to find cure for US boy’s rare disease
- Dead soldier’s DNA in battle against killer disease
- AstraZeneca in good shape for Cambridge move
- BioSilta strengthens team and completes HQ
- F-star launches oncology spin-out
- MedImmune pays $150m for cancer-imaging technology
- Tech spy inside the body will diagnose cancer faster
Page 1 of 67